Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3, 4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio- …
We describe herein the discovery of LASSBio-881 (3c) as a novel in vivo antinociceptive, anti-inflammatory, and in vitro antiproliferative and antioxidant compound, with a cannabinoid ligand profile. We observed that LASSBio-881 (3c) was able to bind to CB1 receptors (71% at 100μM) and also to inhibit T-cell proliferation (66% at 10μM) probably by binding to CB2 receptors, in a non-proapoptotic manner, different from anandamide (1). It ...